Infinium Pharmachem Limited (NSEI: INFINIUM)
Health Care · Pharmaceuticals · IN
Rs239.75
+9.23% today · -6.0% 1Y
Infinium Pharmachem Limited (NSEI: INFINIUM) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $39.07M and employs 144 people.
Over the last twelve months the share price has lost 6.0%, trading between 189.40 and 276.00.
Tweenvest scores Infinium Pharmachem Limited across four factors: quality 68/100, value 61/100, growth 89/100. Its strongest factor is growth.
INFINIUM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $39.07M
- Revenue (TTM)
- $20.22M
- P/E
- 30.74
- EPS
- 7.80
- Dividend yield
- —
- Beta (5Y)
- 0.32
- 52-week high
- Rs276.00
- 52-week low
- Rs189.40
- Avg volume (3M)
- —
- Shares outstanding
- 15.58M
- Employees
- 144
- Next earnings
- —
About Infinium Pharmachem Limited
Infinium Pharmachem Ltd. is a specialized chemical company engaged in the development, manufacture, and export of a wide range of iodine derivatives and Active Pharmaceutical Ingredients (APIs). The company's core focus is on iodine chemistry, providing over 200 iodine derivatives and more than 15 APIs. It also offers Contract Research and Manufacturing Services (CRAMS), which include research and development, process optimization, scale-up, and commercial-scale manufacturing and packaging for iodine-based compounds. Infinium Pharmachem serves diverse global industries such as pharmaceuticals, specialty and performance chemicals, nutraceuticals, animal feed, agriculture, biotech, cosmetics, electronics, and medical imaging. The company operates an ISO, FDA-approved, and GMP-compliant manufacturing facility in Gujarat, India, and supplies its products to markets across India, Europe, Asia, North America, Central America, the Middle East, and South America.
- Founded
- 2003
- Listed since
- Apr 17, 2023
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,256.11 | +0.06% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $271.93 | +0.63% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.78 | +0.15% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.14 | +0.25% |
Figures last refreshed Aug 18, 2026.